• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Vatalanib Dihydrochloride

Vatalanib Dihydrochloride

Product ID V0376
Cas No. 212141-51-0
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $58.50 In stock
5 mg $97.30 In stock
10 mg $127.20 In stock
25 mg $194.70 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Vatalanib is an inhibitor of VEGFR that is currently in clinical trials for the treatment of myelodysplastic syndrome, lymphomas, non-small cell lung cancers (NSCLCs), and other cancers. Vatalanib exhibits anti-angiogenic, anti-metastatic, anticancer chemotherapeutic, and analgesic activities. In animal models with mammary carcinoma allografts, vatalanib decreases tumor vascularization. In animal models of pancreatic carcinoma, vatalanib inhibits tumor growth and metastasis and decreases microvessel density. Additionally, vatalanib decreases chronic neuropathic pain in animal models of chronic constriction injury, as inhibition of VEGFR2 inhibits signaling through neuropathic pain-mediating P2X (2/3) receptors.

Product Info

Cas No.

212141-51-0

Purity

≥98%

Formula

C20H15ClN4 • 2HCl

Formula Wt.

419.73

IUPAC Name

N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine;dihydrochloride

Synonym

PTK-787 Dihydrochloride, PTK 787 Dihydrochloride, PTK787 Dihydrochloride, ZK-222584 Dihydrochloride, ZK 222584 Dihydrochloride, ZK222584 Dihydrochloride, CGP-797870 Dihydrochloride, ZK232934 Dihydrochloride

Melting Point

268-270°C

Appearance

Off-white to pinkish powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

V0376 MSDS PDF

Info Sheet

V0376 Info Sheet PDF

References

Gupta P, Mulkey F, Hasserjian RP, et al. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct;31(5):1311-20. PMID: 23700288.

Liu S, Xu C, Li G, et al. Vatalanib decrease the positive interaction of VEGF receptor-2 and P2X2/3 receptor in chronic constriction injury rats. Neurochem Int. 2012 May;60(6):565-72. PMID: 22361062.

Gauler TC, Besse B, Mauguen A, et al. Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol. 2012 Mar;23(3):678-87. PMID: 21617019.

Hlushchuk R, Riesterer O, Baum O, et al. Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol. 2008 Oct;173(4):1173-85. PMID: 18787105.

Solorzano CC, Baker CH, Bruns CJ, et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm. 2001 Oct;16(5):359-70. PMID: 11776753.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • A8644

    AVL-292

    BTK inhibitor.

    ≥98%
  • T6930

    Triclosan Methyl Ether

    Diarylether; bacterial ENR binder, fatty acid s...

    ≥99%
  • B8144

    Bulleyaconitine A

    Found in Aconitum bulleyanum; voltage-gated Na+...

    ≥95%
  • D5709

    Docetaxel

    Semi-synthetic analog of taxol; microtubule dep...

    ≥98%
  • A001001

    A 83-01

    TGFbeta receptor inhibitor

    ≥98%
  • E499601

    Empagliflozin

    SGLT2 inhibitor

    ≥98%
  • F465818

    Fluorouracil Impurity B

    Fluorouracil impurity

    ≥95%
  • T7037

    Triptorelin Acetate

    Peptide, GnRH analog.

    ≥95%
  • H0002

    H8 dihydrochloride

    PKA inhibitor.

    ≥98%
  • F1607

    Febuxostat

    Xanthine oxidase inhibitor.

    ≥98%
  • R1780

    trans-Retinoic Acid

    Vitamin A carboxylic acid; RAR agonist.

    ≥98%
  • A4617

    Aloe Emodin

    Anthraquinone found in aloe; CTFR Cl- channel a...

    ≥98%
  • P6954

    Pioglitazone Hydrochloride

    Thiazolidinedione; PPARα/γ agonist, mitoNEET ...

    ≥98%
  • B8276

    Butyric Acid Sodium

    HDAC inhibitor, RNA splicing modulator.

    ≥98%
  • E7324

    Ethisterone

    Synthetic steroid hormone, contraceptive; PR ag...

    ≥98%
  • M568266

    Mogroside IIIe

    Triterpenoid

    ≥98%
  • A0248

    BAM-12P

    Peptide, cleavage product of proenkephalin; κO...

    ≥95%
  • A0966

    Adrenocorticotropic Hormone (1-16), human

    Endogenous peptide hormone fragment, involved i...

    ≥95%
  • T3036

    Thienylhexyl Isothiocyanate

    Thienylbutyl ITC analog.

    ≥97%
  • T0109

    13-Acetyl-9-dihydrobaccatin-III

    Found in Taxus, starting material for synthesis...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only